Jounce Therapeutics Achieves First Milestone in Exclusive License Agreement with Gilead Sciences and FDA Clearance of Investigational New Drug Application for Anti-CCR8 Antibody
Psychedelics Investing NeonMind to Present at H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference
Longer-term Data for Kite's Yescarta® in Relapsed or Refractory Follicular Lymphoma Demonstrate Substantial Survival Improvement Over Current Therapies in Comparative Analysis
IMBRUVICA® Plus VENCLEXTA®/VENCLYXTO® Combination Shows Superior Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in First-line Chronic Lymphocytic Leukemia Phase 3 GLOW Study
Perimeter Medical Imaging AI to Participate in Panel Discussion "Innovations in Breast Cancer Detection, Surgery and Treatment" at the Lytham Partners Summer 2021 Investor Conference
Naturally Splendid Announces Select Denny's Canada Restaurants to Offer NATERA Meat Alternative Entrees
Bristol Myers Squibb and Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl® in Adults with Non-Transfusion Dependent Beta Thalassemia
